不孕症研究核心结局指标集的国际共识制定
本研究通过三轮德尔菲调查(372名来自41个国家的参与者)和共识发展研讨会(30名来自27个国家的参与者),制定了用于不孕症治疗随机对照试验和系统评价的核心结局指标集。该指标集包括超声确认的活胎宫内妊娠、妊娠丢失、活产、分娩孕周、出生体重、新生儿死亡和重大先天畸形,并建议在适用时报告导致活产的受孕时间。
要点
- 核心结局指标集包括7项必须报告的核心结局和1项条件性报告结局。
- 该指标集适用于不孕症治疗的随机对照试验和系统评价。
- 超过80家专业期刊和研究资助机构已承诺实施该核心结局指标集。
核心结论
- 已制定不孕症研究的核心结局指标集,以标准化结局的选择、收集和报告。
研究设计与样本
- 采用三轮德尔菲调查(372名参与者,来自41个国家)和共识发展研讨会(30名参与者,来自27个国家),汇集医疗专业人员、研究人员和有不孕问题的人士。
主要发现
- 核心结局指标集包括:超声确认的活胎宫内妊娠(考虑单胎、双胎及多胎妊娠)、妊娠丢失(考虑异位妊娠、流产、死产和终止妊娠)、活产、分娩孕周、出生体重、新生儿死亡和重大先天畸形。
- 在适用时,应报告导致活产的受孕时间。
关键数值与推荐
- 核心结局指标集共包含7项核心结局:活胎宫内妊娠、妊娠丢失、活产、分娩孕周、出生体重、新生儿死亡、重大先天畸形。
- 导致活产的受孕时间应在适用时报告。
临床怎么用
- 在不孕症随机对照试验和系统评价中嵌入该核心结局指标集,以确保核心结局的全面选择、收集和报告。
- 研究资助机构、SPIRIT声明以及超过80家专业期刊(包括Cochrane妇科和生育组、Fertility and Sterility和Human Reproduction)已承诺实施该核心结局指标集。
局限性
- 使用的共识发展方法存在固有局限性,包括参与者样本的代表性、德尔菲调查的失访以及任意的共识阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can a core outcome set to standardize outcome selection, collection and reporting across future infertility research be developed? SUMMARY ANSWER: A minimum data set, known as a core outcome set, has been developed for randomized controlled trials (RCTs) and systematic reviews evaluating potential treatments for infertility. WHAT IS KNOWN ALREADY: Complex issues, including a failure to consider the perspectives of people with fertility problems when selecting outcomes, variations in outcome definitions and the selective reporting of outcomes on the basis of statistical analysis, make the results of infertility research difficult to interpret. STUDY DESIGN, SIZE, DURATION: A three-round Delphi survey (372 participants from 41 countries) and consensus development workshop (30 participants from 27 countries). PARTICIPANTS/MATERIALS, SETTING, METHODS: Healthcare professionals, researchers and people with fertility problems were brought together in an open and transparent process using formal consensus science methods. MAIN RESULTS AND THE ROLE OF CHANCE: The core outcome set consists of: viable intrauterine pregnancy confirmed by ultrasound (accounting for singleton, twin and higher multiple pregnancy); pregnancy loss (accounting for ectopic pregnancy, miscarriage, stillbirth and termination of pregnancy); live birth; gestational age at delivery; birthweight; neonatal mortality; and major congenital anomaly. Time to pregnancy leading to live birth should be reported when applicable. LIMITATIONS, REASONS FOR CAUTION: We used consensus development methods which have inherent limitations, including the representativeness of the participant sample, Delphi survey attrition and an arbitrary consensus threshold. WIDER IMPLICATIONS OF THE FINDINGS: Embedding the core outcome set within RCTs and systematic reviews should ensure the comprehensive selection, collection and reporting of core outcomes. Research funding bodies, the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) statement, and over 80 specialty journals, including the Cochrane Gynaecology and Fertility Group, Fertility and Sterility and Human Reproduction, have committed to implementing this core outcome set. STUDY FUNDING/COMPETING INTEREST(S): This research was funded by the Catalyst Fund, Royal Society of New Zealand, Auckland Medical Research Fund and Maurice and Phyllis Paykel Trust. The funder had no role in the design and conduct of the study, the collection, management, analysis or interpretation of data, or manuscript preparation. B.W.J.M. is supported by a National Health and Medical Research Council Practitioner Fellowship (GNT1082548). S.B. was supported by University of Auckland Foundation Seelye Travelling Fellowship. S.B. reports being the Editor-in-Chief of Human Reproduction Open and an editor of the Cochrane Gynaecology and Fertility group. J.L.H.E. reports being the Editor Emeritus of Human Reproduction. J.M.L.K. reports research sponsorship from Ferring and Theramex. R.S.L. reports consultancy fees from Abbvie, Bayer, Ferring, Fractyl, Insud Pharma and Kindex and research sponsorship from Guerbet and Hass Avocado Board. B.W.J.M. reports consultancy fees from Guerbet, iGenomix, Merck, Merck KGaA and ObsEva. C.N. reports being the Co Editor-in-Chief of Fertility and Sterility and Section Editor of the Journal of Urology, research sponsorship from Ferring, and retains a financial interest in NexHand. A.S. reports consultancy fees from Guerbet. E.H.Y.N. reports research sponsorship from Merck. N.L.V. reports consultancy and conference fees from Ferring, Merck and Merck Sharp and Dohme. The remaining authors declare no competing interests in relation to the work presented. All authors have completed the disclosure form. TRIAL REGISTRATION NUMBER: Core Outcome Measures in Effectiveness Trials Initiative: 1023.
引用
- Duffy JMN, AlAhwany H, Bhattacharya S, et al. Developing a core outcome set for future infertility research: an international consensus development study† ‡. Hum Reprod. 2020. PMID: 33252685. doi:10.1093/humrep/deaa241
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。